BRAF and melanoma: We have selected a panel of eight human melanoma cell lines to further characterize the potential effects of leflunomide as an anti-melanoma drug (Supplementary Table 1), where half habour the BRAFV600E mutation and the remainder are wildtype for BRAF (BRAFWT; Supplementary Table 1).